2.7 million people in the major pharmaceutical markets are
diagnosed with moderate to severe psoriasis. This relatively large population
and the increasing use of biologics to treat the disease have made the therapy
market one of substantial commercial opportunity. In 2011, driven by its better
efficacy and dosing schedule and dermatologists’ positive perception of its
safety profile, adalimumab (AbbVie/Eisai’s Humira) displaced etanercept
(Amgen/Stiefel/Pfizer/Takeda’s Enbrel) as the G7 sales leader. Although the
current moderate to severe psoriasis market is crowded with efficacious
biologics, opportunity still exists for new agents that offer improvements in
short- and long-term efficacy and in safety, particularly a lower risk of
malignancy and serious infections. The moderate to severe psoriasis pipeline
contains several agents with novel mechanisms of action that have the potential
to fulfill these unmet needs.
Attributes included in conjoint analysis-based assessment of target product profiles for moderate to severe psoriasis:
- PASI 75 response at 12 weeks (% of patients achieving a PASI 75 response, placebo-adjusted).
- PASI 90 response at 12 weeks (% of patients achieving a PASI 90 response, placebo-adjusted).
- PASI 75 response at 60 weeks (% of patients achieving a PASI 75 response, NOT placebo-adjusted).
- Risk of serious infections (rate per 100 patient-years, placebo-adjusted).
- LDL cholesterol level (% increase in mean levels relative to baseline).
- Delivery burden (drug formulation and dosing).
Attributes included in assessment of U.S. payers’ receptivity to new therapies for moderate to severe psoriasis:
- Improved effect on PASI 75 response at 12 weeks.
- Improved effect on PASI 75 response at 52-60 weeks.
- Lower rate of serious infections.
- Improved formulation and dosing frequency.
Physicians surveyed: 60 U.S. and 31 European dermatologists.
Payers surveyed: 20 U.S. MCO PDs.
Comprehensive List of Therapies Included in Our Research and Modeling:
- Adalimumab (AbbVie/Eisai’s Humira)
- Etanercept (Amgen/Stiefel/Pfizer/Takeda’s Enbrel)
- Infliximab (Janssen/Merck/Mitsubishi Tanabe’s Remicade)
- Ustekinumab (Janssen’s Stelara)
- Apremilast (Celgene)
- Tofacitinib (Pfizer’s Xeljanz)
- Secukinumab (Novartis)
- Brodalumab (Amgen/AstraZeneca/Kyowa Hakko Kirin)
- MK-3222 (Merck)
- Ixekizumab (Eli Lilly)